Innate Pharma SA Interest Received Classified As Investing Activities
Innate Pharma SA (IPHYF) reported Interest Received Classified As Investing Activities of EUR 388.00 thousand for the 12-month period ending 2025-12-31, per its 20-F filed 2026-04-01.
Financial Statements › Cash Flow › Investing Activities
ifrs-full:InterestReceivedClassifiedAsInvestingActivities · last filed 2026-04-01
| Period end | Interest Received Classified As Investing Activities 6 month | Interest Received Classified As Investing Activities 12 month |
|---|---|---|
| 2025-12-31 | 388.00K EUR 20-F · filed 2026-04-01 | |
| 2024-12-31 | 0.00 EUR 20-F · filed 2026-04-01 | |
| 2023-12-31 | 0.00 EUR 20-F · filed 2026-04-01 | |
| 2023-06-30 | 0.00 EUR 6-K · filed 2023-09-14 | |
| 2022-12-31 | 0.00 EUR 20-F · filed 2024-04-04 | |
| 2022-06-30 | 25.00K EUR 6-K · filed 2023-09-14 | |
| 2021-12-31 | 367.00K EUR 20-F · filed 2024-04-04 | |
| 2021-06-30 | 86.00K EUR 6-K · filed 2022-09-15 | |
| 2020-12-31 | 962.00K EUR 20-F · filed 2023-04-06 | |
| 2020-06-30 | 758.00K EUR 6-K · filed 2021-09-15 | |
| 2019-12-31 | 1.29M EUR 20-F · filed 2022-04-04 | |
| 2018-12-31 | 1.45M EUR 20-F · filed 2021-04-27 | |
| 2017-12-31 | 1.44M EUR 20-F · filed 2020-04-24 |